The envelope glycoprotein trimer mediates HIV-1 entry into cells. The trimer is flexible, fluctuating between closed and more open conformations and sometimes sampling the fully open, CD4-bound form. We hypothesized that conformational flexibility and transient exposure of non-neutralizing, immunodominant epitopes could hinder the induction of broadly neutralizing antibodies (bNAbs). We therefore modified soluble Env trimers to stabilize their closed, ground states. The trimer variants were indeed stabilized in the closed conformation, with a reduced ability to undergo receptor-induced conformational changes and a decreased exposure of non-neutralizing V3-directed antibody epitopes. In rabbits, the stabilized trimers induced similar autolog...
<div><p>The trimeric envelope (Env) spike is the focus of vaccine design efforts aimed at generating...
<div><p>A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) ...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
The envelope glycoprotein trimer mediates HIV-1 entry into cells. The trimer is flexible, fluctuatin...
HIV-1 has evolved various tricks to prevent the development of a potent humoral immune response. The...
Purpose of review To provide an update on the latest developments in the field of HIV-1 antibody-bas...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV-1 antibo...
The HIV-1-envelope glycoprotein (Env) is the main target of antigen design for antibody-based prophy...
The production of native-like recombinant versions of the HIV-1 envelope glycoprotein (Env) trimer r...
The production of native-like recombinant versions of the HIV-1 envelope glycoprotein (Env) trimer r...
Summary: The HIV-1-envelope glycoprotein (Env) is the main target of antigen design for antibody-bas...
The trimeric envelope glycoproteins (Env) on the surface of HIV-1 virions are the targets for neutra...
A successful HIV-1 vaccine will likely need to elicit broadly neutralizing antibodies (bNAbs) that t...
Evidence from active and passive vaccination trials suggests that both non-neutralizing and neutrali...
<div><p>The trimeric envelope (Env) spike is the focus of vaccine design efforts aimed at generating...
<div><p>A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) ...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
The envelope glycoprotein trimer mediates HIV-1 entry into cells. The trimer is flexible, fluctuatin...
HIV-1 has evolved various tricks to prevent the development of a potent humoral immune response. The...
Purpose of review To provide an update on the latest developments in the field of HIV-1 antibody-bas...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV-1 antibo...
The HIV-1-envelope glycoprotein (Env) is the main target of antigen design for antibody-based prophy...
The production of native-like recombinant versions of the HIV-1 envelope glycoprotein (Env) trimer r...
The production of native-like recombinant versions of the HIV-1 envelope glycoprotein (Env) trimer r...
Summary: The HIV-1-envelope glycoprotein (Env) is the main target of antigen design for antibody-bas...
The trimeric envelope glycoproteins (Env) on the surface of HIV-1 virions are the targets for neutra...
A successful HIV-1 vaccine will likely need to elicit broadly neutralizing antibodies (bNAbs) that t...
Evidence from active and passive vaccination trials suggests that both non-neutralizing and neutrali...
<div><p>The trimeric envelope (Env) spike is the focus of vaccine design efforts aimed at generating...
<div><p>A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) ...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...